volinanserin
Phase 3Small molecule
Sanofivolinanserin is one of 72 small molecule programs targeting Insomnia. It is currently in Phase 3.
2
Indications
4
Total Trials
0
Active Trials
71
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
286 competitors in Diabetes Mellitus
#DrugCompanyPhaseTrials
1Glucagon
XXeris Pharmaceuticals
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Genotropin
EMD SeronoPhase 3
volinanserin
SanofiPhase 3
Trulicity
Eli LillyPreclinical
Byetta
AstraZenecaPreclinical
NOVOLIN R
Novo NordiskPreclinical
Galvus
NovartisPreclinical
Simponi
Johnson & JohnsonPreclinical
Paxil CR
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Diabetes Mellitus2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for volinanserin. EMBL-EBI & Wellcome Sanger Institute.
- [4]